Skip to content Skip to footer
Subscribe Now
Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots
VIEWPOINTS

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots 

Shots:  Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery  Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding  Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
August 20, 2025

Read more

VIEWPOINTS

Healthcare Marketing: Tom Donnelly from Supreme Group in a Stimulating Dialogue Exchange with PharmaShots 

Shots:  Supreme Group recently announced its 8th acquisition, adding Nimble Works and Vital Works to its portfolio, strengthening its presence in healthcare marketing and communications  The acquisition brings together Nimble Works’ insight-driven creative strengths and Vital Works’ performance-focused digital expertise to navigate complex healthcare domains and accelerate data-driven growth marketing  Tom Donnelly, CEO of Supreme…
August 6, 2025

Read more

Viewpoints_Tahi Ahmadi
VIEWPOINTS

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots:  Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms  Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab  With this acquisition, Genmab…
July 29, 2024

Read more

VIEWPOINTS_Nathan McCutcheon_2023
VIEWPOINTS

Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi

Shots:  Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi   Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline   The acquisition provides Shionogi exclusive development, manufacturing,…
October 16, 2023

Read more

Top Performing Drug – Enbrel (June Edition)
INSIGHTS+

Top Performing Drug – Enbrel (June Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…
June 28, 2023

Read more

VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023
VIEWPOINTS

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots: Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platform Mark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
May 4, 2023

Read more

Viewpoints_Meghan Scanlon
VIEWPOINTS

PharmaShots Interview: Boston Scientific’s Meghan Scanlon Shares Insight on the Completion of its $1.07B Lumenis Acquisition

In an interview with PharmaShots, Meghan Scanlon, Senior Vice President and President for Urology and Pelvic Health at Boston Scientific shares her views on the completion of its $1.07B  acquisition of Lumenis surgical business Shots: Boston Scientific reported the closing of its acquisition of the Lumenis surgical business from a BPEA affiliate for an upfront of $1.07B. The acquisition follows the Mar…
December 20, 2021

Read more

Viewpoints_Gilles Cottier
VIEWPOINTS

PharmaShots Interview: Aceto’s Gilles Cottier Shares Insight on the Acquisition of A&C and IsleChem

In an interview with PharmaShots, Gilles Cottier, Chief Executive Officer of Aceto shared his views on the acquisitions of A&C and IsleChem to highlight the company's growth strategy. Shots: The acquisition of IsleChem has allowed the company to expand its manufacturing expertise in the US. Aceto currently has diversified access to a robust global supply chain network The acquisition…
May 11, 2021

Read more